Alltracel promises ‘exciting’ future

SHAREHOLDERS in Alltracel Pharmaceuticals were promised an “exciting” future yesterday as the first aid product developer said first-half losses fell from €2.2 million to €1.9m.

The Sallynoggin-based company, which develops wound care treatments, said revenue surged from €1.98m to €8.37m in the six months to June. Operating losses eased from €1.8m to €1.5m before interest expenses.

Chief executive Tony Richardson said the results were pleasing and that he remained comfortable with a full-year revenue forecast of €21m. Mr Richardson, who took over from company founder Gerry Brandon last year, said the company was benefiting from recent acquisitions and that cross-selling benefits and associated cost savings were already kicking in.